# New Drug Targets Muscle Loss From Weight Loss Injections
Weight loss medications like semaglutide and tirzepatide deliver dramatic results, but they carry an overlooked cost. About one-third of the weight people lose on these obesity injections comes from muscle rather than fat, researchers report.
This muscle wasting, nicknamed "Ozempic butt," creates a metabolic problem. Losing muscle mass slows your metabolism, makes future weight regain easier, and weakens the body. People on these medications often notice sagging skin and a diminished, deflated appearance even as the number on the scale drops.
Now scientists are developing a new drug to prevent this side effect. The medication works alongside weight loss injections to preserve lean muscle tissue while the body burns through fat stores. Researchers aim to prevent the metabolic consequences that follow aggressive weight loss without muscle support.
The mechanism matters here. Obesity medications suppress appetite and improve insulin sensitivity, but they don't distinguish between fat and muscle during weight loss. Your body preferentially burns muscle when calories drop sharply, especially without resistance exercise to signal muscles should be preserved.
Healthcare providers increasingly recommend strength training alongside these medications to counteract muscle loss. Yet many patients don't have access to consistent fitness guidance or the physical capacity to exercise during rapid weight loss.
A pharmaceutical solution addresses this gap. By blocking muscle breakdown pathways while weight loss medications work, the new drug could help people maintain strength and metabolic health throughout treatment. This combination approach reflects a shift toward smarter obesity management, one that accounts for body composition rather than focusing solely on weight.
The strategy aligns with emerging evidence that how you lose weight matters as much as how much you lose. Preserving muscle protects long-term health outcomes and makes weight maintenance more sustainable.